Logistics Development Group — Portfolio NAV Update

NAV per share rose 6.2%, but profit and cash flow details remain undisclosed.

What the company is saying

Logistics Development Group plc reports a 6.2% increase in unaudited estimated NAV per share to 28 pence as of 30 June 2026, attributing this primarily to a revaluation of Alliance Pharma Limited. The company highlights a portfolio fair value of £113.7 million (excluding cash) and details economic interests and investment at cost for each major holding. Management describes portfolio company performance as 'robust', 'resilient', and 'strong', referencing operational initiatives such as factory automation at Finsbury Food Group Limited and innovation pipelines at Alliance Pharma Limited. The announcement emphasizes future growth potential, AI integration, and new product launches, particularly for Kelo-Cote and Nizoral in 2027. Forward-looking statements are prominent, with management expressing confidence in the portfolio's medium-term prospects. The language is upbeat and focuses on qualitative achievements, while omitting detailed financial metrics for profitability, cash flow, or valuation methodology beyond headline NAV and fair value figures.

What the data suggests

The only quantified improvement is the unaudited estimated NAV per share, which increased by 6.2% to 28 pence over the quarter. The investment portfolio's fair value is stated as £113.7 million, but no comparative figure for the prior period is provided. Economic interests in major holdings are specified: 25.31% in Finsbury Food Group Limited, 10.62% in SQLI SA, 24.54% in Alliance Pharma Limited, and 38.25% in WS Holdco Limited, with corresponding investments at cost and revenue figures for each. The NAV increase is explicitly linked to a revaluation of Alliance Pharma Limited, previously held at cost. No profit, EBITDA, or cash flow data is disclosed for LDG or its portfolio companies. Operational claims about cost efficiencies, growth drivers, and innovation pipelines are not supported by numerical evidence. The data is sufficient for a high-level NAV update but lacks transparency on underlying profitability, cash generation, or valuation methodology.

Analysis

The announcement's tone is upbeat, highlighting a 6.2% increase in NAV per share and describing portfolio company performance as 'robust', 'resilient', and 'strong'. However, the only realised, measurable progress is the NAV per share increase, which is unaudited and driven by a revaluation of a single holding (Alliance Pharma Limited). No profitability metrics (net income, EBITDA, operating profit, or cash flow) are disclosed for LDG or its portfolio companies, limiting the ability to assess whether growth is translating into sustainable value. Several claims about operational improvements, cost efficiencies, and future product launches are forward-looking or qualitative, with no supporting numerical evidence. The language inflates the signal by using subjective descriptors and projecting future benefits without quantification. The data supports a weak_positive signal due to the NAV increase, but the lack of profit data and reliance on narrative over evidence prevents a stronger rating.

Risk flags

• ●The NAV per share figure is unaudited and relies on internal valuation practices, introducing the risk that actual asset values may differ from reported estimates if subjected to external audit or market testing.
• ●No profitability, EBITDA, or cash flow data is disclosed for LDG or its portfolio companies, making it impossible to assess whether NAV growth is translating into sustainable earnings or liquidity. This lack of transparency limits the ability to evaluate true financial health.
• ●The increase in NAV is attributed to a revaluation of Alliance Pharma Limited, which was previously held at cost. Without detail on the valuation methodology or market comparables, there is a risk that this uplift may not be realised if market conditions change or if the valuation proves optimistic.

Bottom line

This quarterly update shows a 6.2% increase in unaudited NAV per share, driven by a revaluation of Alliance Pharma Limited, but provides no profit, EBITDA, or cash flow figures for LDG or its portfolio companies. The announcement relies heavily on qualitative descriptions of operational progress and future growth potential, with little supporting numerical evidence for these claims. The lack of detailed financial disclosures means investors cannot assess whether NAV gains are sustainable or backed by underlying earnings. While the NAV increase is a positive signal, its unaudited nature and reliance on internal valuation practices add uncertainty. For this update to be actionable, the company would need to provide audited figures and detailed profit and cash flow data. The most important takeaway is that headline NAV growth is not a substitute for demonstrated profitability or cash generation.

Announcement summary

(LSE:LDG) Logistics Development Group plc announced its quarterly portfolio data, reporting an unaudited estimated net asset value ("NAV") per share of 28 pence as at 30 June 2026, reflecting an increase of 6.2% compared to 31 March 2026. LDG's investment portfolio represents a fair value of £113.7 million (excluding cash). Finsbury Food Group Limited delivered a robust Q2 2026 performance, with growth driven by the Lola's and Flower and White acquisitions and profitability growth underpinned by investment in factory automation. SQLI SA delivered a resilient Q2 2026 performance, with underlying demand across its core end-to-end e-commerce offering remaining solid and a return to growth in France. Alliance Pharma Limited delivered a strong first half, with growth driven in particular by Kelo-Cote, and management expects revenues from new products to exceed the 2026 target by more than £1m. During Q2 2026, WS Holdco Limited acquired Walkers Transport Holdings Limited and Madex Logistics Limited, with LDG's economic interest in WS Holdco at 38.25% as at 30 June 2026. The Manager believes the portfolio is well positioned to continue to deliver a robust return in the medium term.

Disagree with this article?